(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 January 2009 (29.01.2009)

PCT

(10) International Publication Number
WO 2009/013335 A1

(51) International Patent Classification:
A61P 21/00 (2006.01) *A61P 1/16* (2006.01)
C07D 487/04 (2006.01) *A61P 19/00* (2006.01)
A61P 25/00 (2006.01) *A61K 31/5025* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:
PCT/EP2008/059705

(22) International Filing Date: 24 July 2008 (24.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07113214.6 26 July 2007 (26.07.2007) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LIZOS, Dimitros** [GR/CH]; Offenburgerstrasse 47, CH-4057 Basel (CH). **WEILER, Sven** [DE/DE]; Adlergässchen 6, LÖRRACH 79539 (DE). **STIEFL, Nikolaus Johannes** [DE/DE]; Pestalozzistrasse 45, 79540 Lörrach (DE).

(74) Agent: **VOEGELI-LANGE, Regina**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*

(54) Title: ORGANIC COMPOUNDS



(I)

(57) Abstract: Compounds of formula (I) in free or salt or solvate form, where R1, R2 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

WO 2009/013335 A1